A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF V114 IN HEALTHY INFANTS (PNEU-LINK)/ PROTOCOL 031-00
- Registry ID
- V114-031
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- MERCK CANADA INC
- Start date
- 2018-12-14
- Last update
- 2018-11-28
Conditions
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY,
TOLERABILITY, AND IMMUNOGENICITY OF V116 IN CHILDREN AND ADOLESCENTS
WITH INCREASED RISK OF PNEUMOCOCCAL DISEASE
- A PHASE 2 MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND, DOSE-RANGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A 25-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY PCV-NAÏVE ADULTS
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V116 IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 TO 64 YEARS OF AGE WITH INCREASED RISK FOR PNEUMOCOCCAL DISEASE
- A PHASE 3 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY,AND IMMUNOGENICITY OF V116 IN PNEUMOCOCCAL VACCINE-EXPERIENCED ADULTS 50 YEARS OF AGE OR OLDER
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V114 IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER (PNEU-AGE)
View on source registry